Amylyx Pharmaceuticals Inc Q1 2024 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Corinne Johnson - Goldman Sachs - Analyst : Good morning guys, maybe a couple from us. Just first, in terms of the cash runway guidance into '26, I guess what specific trials and then readout should be embedded with in that guidance? And then how should we think about the trial design and your expectations for the Phase 1 study of AMX0014 and then when can we get that data? Thanks.

Question: Corinne Johnson - Goldman Sachs - Analyst : Great.

Question: Graig Suvannavejh - Mizuho Securities - Analyst : Hi, good morning. Thank you for taking the questions. I have one, just in particular around the expectation of getting the final data with respect to Wolfram. And I'm just wondering, is there any potential that what you see in the final changes, the interpretation of the findings of your interim data? And then secondly, just maybe on your calpain program, you had mentioned that there are perhaps a dozen different calpain and you've chosen the Calpain-2. So, I'm just wondering, of that dozen, what gives you the confidence that Calpain-2 is the right one to go after in ALS? Thanks.

Question: Graig Suvannavejh - Mizuho Securities - Analyst : Thanks.